Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Avrobio Inc (AVRO)
NASDAQ:AVRO
Avrobio (AVRO) Stock Price & Analysis
295 Followers
AVRO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.56 - $1.93
Previous Close$1.18
Volume547.37K
Average Volume (3M)2.12M
Market Cap
$48.30M
Enterprise Value-$1.95M
Total Cash (Recent Filing)$72.33M
Total Debt (Recent Filing)$18.34M
Price to Earnings (P/E)-0.5
Beta1.85
Next Earnings
Aug 10, 2023EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.31
Shares Outstanding44,105,078
10 Day Avg. Volume11,102,554
30 Day Avg. Volume2,124,811
Standard Deviation0.23
R-Squared0.14
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.96
Price to Sales (P/S)2262.78
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-42.33
Enterprise Value/Gross Profit-0.65
Enterprise Value/Ebitda0.02
Forecast
1Y Price Target
$3.75Price Target Upside242.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Avrobio News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVRO FAQ
What was Avrobio Inc’s price range in the past 12 months?
Avrobio Inc lowest stock price was $0.56 and its highest was $1.93 in the past 12 months.
What is Avrobio Inc’s market cap?
Currently, no data Available
When is Avrobio Inc’s upcoming earnings report date?
Avrobio Inc’s upcoming earnings report date is Aug 10, 2023 which is in 71 days.
How were Avrobio Inc’s earnings last quarter?
Avrobio Inc released its earnings results on May 11, 2023. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.545 by -$0.025.
Is Avrobio Inc overvalued?
According to Wall Street analysts Avrobio Inc’s price is currently Undervalued.
Does Avrobio Inc pay dividends?
Avrobio Inc does not currently pay dividends.
What is Avrobio Inc’s EPS estimate?
Avrobio Inc’s EPS estimate is -$0.56.
How many shares outstanding does Avrobio Inc have?
Avrobio Inc has 44,105,080 shares outstanding.
What happened to Avrobio Inc’s price movement after its last earnings report?
Avrobio Inc reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.545. Following the earnings report the stock price went down -2.985%.
Which hedge fund is a major shareholder of Avrobio Inc?
Among the largest hedge funds holding Avrobio Inc’s share is GMT Capital Corp. It holds Avrobio Inc’s shares valued at 4M.
---
Avrobio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.75 (242.47% Upside)
$3.75 (242.47% Upside)
Hedge Fund Trend
Increased
By 3.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▲ 12.2%
Last 30 Days ▲ 12.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.09%
12-Months-Change
Fundamentals
Return on Equity
-102.99%
Trailing 12-Months
Asset Growth
-52.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Avrobio Inc
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding AVRO
iShares Core S&P Total U.S. Stock Market ETF
$53.10
Up to five ETFs with an Outperform Smart Score that hold AVRO. The ETFs are listed according to market value of AVRO within the ETF
---
TScan Therapeutics
―
Synaptogenix
―
Protara Therapeutics
―
Unity Biotechnology
―
MAIA Biotechnology, Inc.
―
---